Strongyloides Stercoralis Test · Stool

A worm you picked up decades ago, in a place you may have long since left, can still be living inside you right now. Strongyloides stercoralis can survive for decades in the human gut without causing obvious symptoms, and then turn life-threatening when your immune system is suppressed by steroids, transplant drugs, or a new illness.

If you grew up in or spent time in a tropical or subtropical region, traveled in rural areas abroad, or are about to start immunosuppressive treatment, knowing whether you carry this parasite can change what happens to you. Standard stool and blood panels usually miss it entirely, so this infection routinely goes undiagnosed until it becomes an emergency.

What Strongyloides Stercoralis Actually Is

Strongyloides stercoralis is a thread-like intestinal worm, a type of parasite scientists call a helminth. Infective larvae (the parasite's tiny juvenile form) in contaminated soil penetrate intact skin, travel through the body, and settle in the small intestine. Unlike most worms, this one can reproduce inside you without re-exposure, a process called autoinfection, which is why a single contact years ago can still be relevant today.

Hundreds of millions of people worldwide are estimated to carry the parasite, with the highest burdens in Southeast Asia, the Western Pacific, and Africa. It is increasingly recognized in migrants, travelers, and older adults with past exposure living in higher-income countries.

Why This Infection Matters

The problem with Strongyloides is not usually the chronic phase. Most people with long-standing infection feel fine or have vague symptoms like intermittent abdominal pain, diarrhea, cough, or a recurring rash. The real danger is what happens when the immune system drops its guard.

Hyperinfection and Dissemination

In people taking steroids, receiving organ transplants, being treated for cancer, or infected with HTLV-1 (a virus that weakens immune control of the parasite), the worm population can suddenly explode. Larvae flood the gut and lungs in what clinicians call hyperinfection, and can spread to multiple organs including the brain and bloodstream in disseminated disease. A systematic review of 339 severe cases reported a mortality rate of about 45%, with septic shock, infectious complications, and lack of treatment as the main risk factors.

In a multicenter case-control study of kidney transplant recipients, severe Strongyloides infection was associated with substantial death and illness, and the risk was highest in the first three months after transplant. In one large French ICU case series of hyperinfection syndrome, outcomes were particularly poor when patients also had shock and required mechanical ventilation.

Co-Infections That Make Things Worse

Carrying Strongyloides also seems to worsen other infections. In a study of 483 adults with pulmonary tuberculosis, those also infected with Strongyloides had more severe disease, higher bacterial burden, and worse treatment outcomes. Meta-analysis data show Strongyloides is more common in people living with HTLV-1, and co-infected patients more often develop severe presentations and fail treatment. Chronic strongyloidiasis has also been linked to invasive bacterial infections originating from the gut.

What the Test Actually Measures

This is not a test of a hormone, protein, or metabolite your body makes. It is a test for the presence of a living organism. Because Strongyloides is a parasite, there is no healthy low level. The only desirable result is no evidence of infection. The test result is essentially binary: either the parasite or your immune response to it is detectable, or it is not.

Different labs use different approaches. Stool microscopy looks for larvae directly but misses most chronic infections because the parasite sheds intermittently and in low numbers. Serology (blood tests for antibodies against Strongyloides, such as IgG and IgG4 ELISAs) detects the immune response to the parasite and catches far more chronic cases. Molecular tests like PCR look for parasite DNA in stool or other samples and are useful when sensitivity matters most, such as in people about to receive immunosuppressive treatment.

Who Is Most at Risk

Epidemiologic studies consistently identify the same risk factors: birth or extended time in endemic regions, male sex, older age, lower socioeconomic status, occupational soil contact, and co-infections like HIV or HTLV-1. In a South Indian adult cohort of 2,351 people, 33% tested seropositive, with higher rates in men and in those 55 and older.

In the US Military Health System, risk of infection was sharply higher in people born in Latin America and the Caribbean, sub-Saharan Africa, and East Asia and the Pacific compared with those born in Europe or North America, with risk ratios of roughly 22 to 34. In haemodialysis patients in Vienna, male sex, eosinophilia, and birth in the Middle East or North Africa were associated with seropositivity. Men who have sex with men may also acquire infection through sexual routes, particularly those with HIV, multiple partners, or oro-anal contact.

Reference Ranges and Result Interpretation

Unlike cholesterol or blood sugar, there are no graded reference ranges for Strongyloides. This is a qualitative test: positive, negative, or equivocal. No published research proposes optimal or ideal levels, because any established infection is considered abnormal and treatable.

The table below reflects how results are interpreted in research and clinical practice. Performance varies by assay and population, so compare your results within the same lab over time for the most meaningful interpretation.

How Accurate Is the Test

No single test catches every case. Stool microscopy has very low sensitivity for chronic infection because the parasite sheds larvae intermittently. Baermann technique and agar plate culture improve detection but can still miss many infections, with single-method sensitivities in some studies as low as 5 to 28%. Serologic tests perform better for chronic, low-level infections. In one study, a two-tier approach combining an ELISA screen with a confirmatory Western blot reached about 96% sensitivity and 99% specificity.

A diagnostic evaluation of five serologic tests found NIE-LIPS to be the most accurate overall, with IFAT and several ELISAs also suitable for diagnosis. Newer IgG4 rapid tests show good accuracy in eosinophilic populations. PCR is highly specific but less sensitive than parasitological methods, making it better for confirmation than for initial screening.

When Results Can Be Misleading

Several factors can produce a false sense of security or a confusing result:

• Recent or acute infection: Serologic assays can miss travelers with recent exposure because antibody responses take time to develop. A negative test soon after potential exposure does not rule out infection.
• Cross-reactivity with other parasites: Antibody tests can react to other helminth infections, causing false positives in people with past exposure to related worms.
• Profound immunosuppression: Eosinophilia (raised eosinophil counts, a type of white blood cell) is present in about 70 to 80% of chronic cases and often used as a clue, but it can be absent in people with severe immune suppression, exactly the group at highest risk of severe disease.
• Prior treatment: If you have taken ivermectin recently, antibody levels may still be elevated even though the parasite has been cleared, so timing of testing matters for interpretation.

Tracking Your Trend

A single test is a snapshot, and for Strongyloides, it matters most at two moments: when you first want to know if you are carrying the parasite, and after treatment to confirm it is gone. A systematic review and meta-analysis of clinical features before and after treatment showed that symptoms and eosinophilia both decline after effective therapy, and serologic antibody levels typically fall over months.

If your initial test is negative but your exposure history is strong, retest with a more sensitive method (serology plus stool PCR if available) before starting immunosuppression. If your test is positive and you have been treated with ivermectin, follow-up testing at around 6 to 12 months helps confirm cure. A rising antibody level after treatment or persistent larvae on stool testing suggests treatment failure and warrants further evaluation.

Decision Pathway for a Positive Result

A positive Strongyloides result is actionable. The first step is treatment with ivermectin, the drug of choice, which in observational and trial data has cure rates around 90 to 98% in uncomplicated chronic infection. In an Ethiopian study of 190 adults, ivermectin produced a 90% cure rate.

Alongside treatment, a positive result should prompt a few targeted investigations. Ask your clinician about testing for HTLV-1, which dramatically changes the risk of severe disease and may require a different treatment approach. If you are scheduled for an organ transplant, cancer therapy, or a course of high-dose steroids, treatment should happen before immunosuppression begins whenever possible. Household contacts who shared the same exposure history may also benefit from testing. Complicated or disseminated disease requires inpatient management, often with prolonged or daily ivermectin until stool and sputum are clear, and carries a substantial mortality risk even with treatment.

Why Standard Panels Are Not Enough

Routine stool tests designed to find common parasite eggs have very low sensitivity for Strongyloides. A normal complete blood count and basic metabolic panel tell you nothing about whether you carry this parasite. Eosinophilia is a hint but not a reliable screen, since it can be absent in the people at highest risk. If your exposure profile fits and the question matters for your health decisions, you need a test that looks for Strongyloides specifically, not the standard workup.